Company: EUDAW
Filing Date: 2025-12-04
Form Type: 424B5
Source: 0001493152-25-026224
Chunk: 22

Company: EUDA Health Holdings Ltd
Filing Date: 2025-12-04
Form: 424B5
Chunk 22
---
’ deficit                                                                                                                              |     |                     |  (3,709,565 | ) |     |             | 12,017,500 |   |     |                       |   8,307,935 |   |
| Noncontrolling interest                                                                                                                                  |     |                     |     (16,755 | ) |     |             |          - |   |     |                       |     (16,755 | ) |
| Total shareholders’ deficit                                                                                                                              |     |                     |  (3,726,320 | ) |     |             | 12,017,500 |   |     |                       |   8,291,180 |   |

You should read this capitalization table in conjunction with Use of Proceeds, the financial statements and notes thereto and other financial information incorporated by reference into this prospectus and any prospectus supplement. Our historical results do not necessarily indicate our expected results for any future periods.

| S-15 |

<div align='center'>PLAN OF DISTRIBUTION/SELLING SHAREHOLDER</div>

We are offering, in a registered direct offering to Streeterville Capital, LLC, an accredited investor (the “Investor”), a convertible warrant (the “Warrant”) for an aggregate purchase price of $100,000 (before fees and expenses). Upon issuance, the Warrant will be immediately exercisable into 2,000,000 newly-issued ordinary shares, no par value each, of the Company (the “Warrant Shares”) at an exercise price of $6.00 per share (the “Exercise Price”) for ninety (90) days (unless extended by mutual agreement) from the issuance date (the “Cash Exercise Period”). During the Cash Exercise Period, the Warrant can only be exercised for cash and the Company will have the right to require the Investor to exercise the Warrant up to 10% of the cumulative dollar trading volume during the Measurement Period (the “Forced Exercise”) if (i) the closing price of the Company’s ordinary shares on Nasdaq is at or above $7.50 for five (5) consecutive trading days (the “Measurement Period”); and (ii) the cumulative trading dollar volume over the Measurement Period (the “Cumulative Volume”) is at least $1,500,000. For a period of two (2) weeks following the end of the Cash Exercise Period (the “Repurchase Period”), the Company will have the right to repurchase any remaining portion of the then outstanding Warrant in cash for $0.